UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

Brain (London, England : 1878), 2019-07, Vol.142 (7), p.1894-1904

2019

Volltextzugriff (PDF)

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine

Headache, 2020-11, Vol.60 (10), p.2304-2319

2020

Volltextzugriff (PDF)

Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine

Journal of child and adolescent psychopharmacology, 2014-10, Vol.24 (8), p.426-434

2014

Volltextzugriff (PDF)

Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment

Journal of child and adolescent psychopharmacology, 2014-10, Vol.24 (8), p.419-425

2014

Volltextzugriff (PDF)

Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies

The journal of clinical psychiatry, 2013-03, Vol.74 (12), p.1217-1223

2013

Volltextzugriff (PDF)

Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials

CNS neuroscience & therapeutics, 2016-07, Vol.22 (7), p.546-557

2016

Volltextzugriff (PDF)

Differential Response Profiles in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Treatment With Atomoxetine

Clinical pediatrics, 2015-02, Vol.54 (2), p.164-173

2015

Volltextzugriff (PDF)

Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States

Child and adolescent psychiatry and mental health, 2010-12, Vol.4 (1), p.31-31, Article 31

2010

Volltextzugriff (PDF)

Sustained Reduction of Migraine Headache Days in Patients with Episodic Migraine During Months 4 to 6 of Treatment with Galcanezumab (1768)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder

Journal of child and adolescent psychopharmacology, 2009-12, Vol.19 (6), p.719-730

2009

Volltextzugriff (PDF)

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Neurology, 2018-12, Vol.91 (24), p.e2222

2018

Volltextzugriff (PDF)

Does Wearing-Off of Efficacy Occur in Galcanezumab-Treated Patients at the End of the Monthly Treatment Cycle: A Post Hoc Analysis of Four Phase 3 Randomized Trials (1922)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Changes in Work Productivity and Interictal Burden: Results from a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Galcanezumab in Adults with Treatment-Resistant Migraine (CONQUER) (700)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexia

Child and adolescent psychiatry and mental health, 2009-12, Vol.3 (1), p.40-40, Article 40

2009

Volltextzugriff (PDF)

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials

Headache, 2022-02, Vol.62 (2), p.198-207

2022

Volltextzugriff (PDF)

A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist

Headache, 2022-10, Vol.62 (9), p.1164-1176

2022

Volltextzugriff (PDF)

Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms

Journal of child and adolescent psychopharmacology, 2017-02, Vol.27 (1), p.38-42

2017

Volltextzugriff (PDF)

Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine (S50.008)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Évolution de la productivité au travail/l’impact des migraines entre les crises : résultats d’une étude clinique randomisée, en double aveugle et contrôlée vs placebo sur le galcanézumab chez des adultes souffrant de migraine difficile à traiter (CONQUER)

Revue neurologique, 2021-04, Vol.177, p.S28-S28

2021

Volltextzugriff (PDF)

Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial

Journal of child and adolescent psychopharmacology, 2017-02, Vol.27 (1), p.19-28

2017

Volltextzugriff (PDF)

Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial

Clinical neuropharmacology, 2011-03, Vol.34 (2), p.51-60

2011

Volltextzugriff (PDF)

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial

Journal of child and adolescent psychopharmacology, 2013-11, Vol.23 (9), p.605-613

2013

Volltextzugriff (PDF)

Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning

Clinical neuropharmacology, 2012-05, Vol.35 (3), p.125-133

2012

Volltextzugriff (PDF)

Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD

Current medical research and opinion, 2010-09, Vol.26 (9), p.2087-2095

2010

Volltextzugriff (PDF)

Atomoxetine for the treatment of Attention-Deficit/Hyperactivity Disorder

Child and adolescent psychiatry and mental health, 2009-12, Vol.3, p.40

2009

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(26)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(16)
Female
(15)
Male
(15)
Attention Deficit Disorder With Hyperactivity - Drug Therapy
(12)
Double-Blind Method
(12)
Treatment Outcome
(12)
Adolescent
(11)
Attention Deficit Hyperactivity Disorder
(10)
Adult
(9)
Atomoxetine Hydrochloride
(9)
Pharmacology & Pharmacy
(9)
Child
(8)
Neurosciences & Neurology
(8)
Adrenergic Uptake Inhibitors - Therapeutic Use
(7)
Clinical Neurology
(7)
Pediatrics
(7)
Propylamines - Therapeutic Use
(7)
Psychiatry
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine

Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine

Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment

Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies

Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials

Differential Response Profiles in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Treatment With Atomoxetine

Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States

Sustained Reduction of Migraine Headache Days in Patients with Episodic Migraine During Months 4 to 6 of Treatment with Galcanezumab (1768)

Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Does Wearing-Off of Efficacy Occur in Galcanezumab-Treated Patients at the End of the Monthly Treatment Cycle: A Post Hoc Analysis of Four Phase 3 Randomized Trials (1922)

Changes in Work Productivity and Interictal Burden: Results from a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Galcanezumab in Adults with Treatment-Resistant Migraine (CONQUER) (700)

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexia

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials

A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist

Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms

Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine (S50.008)

Évolution de la productivité au travail/l’impact des migraines entre les crises : résultats d’une étude clinique randomisée, en double aveugle et contrôlée vs placebo sur le galcanézumab chez des adultes souffrant de migraine difficile à traiter (CONQUER)

Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial

Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial

Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning

Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD

Atomoxetine for the treatment of Attention-Deficit/Hyperactivity Disorder

Suchergebnisse filtern